Damien Roche1,2, Martin Badard3, Laurent Boyer4, Pierre Lafforgue3, Thao Pham3. 1. APHM, CHU Sainte-Marguerite, Rheumatology Department, Aix Marseille Univ., Marseille, France. droche@hopital-saint-joseph.fr. 2. Rheumatology Department, Saint Joseph Hospital, 26 Boulevard de Louvain, 13285, Marseille, France. droche@hopital-saint-joseph.fr. 3. APHM, CHU Sainte-Marguerite, Rheumatology Department, Aix Marseille Univ., Marseille, France. 4. School of Medicine, La Timone Medical Campus, EA 3279: CEReSS - Health Service Research and Quality of life Center, Aix Marseille Univ., Marseille, France.
Abstract
BACKGROUND: Anterior uveitis (AU) is the most frequent extra-articular feature of axial spondyloarthritis (axSpA). We aimed to assess and compare the incidence of AU in axSpA patients treated with anti-TNF or anti-IL17A. METHODS: We systematically reviewed PubMed, EMBase, and Cochrane from inception to May 3, 2020, and searched for placebo-controlled and head-to-head randomized controlled trials (RCTs) assessing anti-TNF monoclonal antibodies (mAb) or soluble receptor fusion protein or anti-IL17A in patients with axSpA according to ASAS criteria and reporting safety data on AU. Data were extracted following a predefined protocol. We did pairwise and network meta-analyses for the primary outcome of AU flares (relapse or de novo) incidence and estimated summary odds ratios (ORs). We assessed the quality of evidence using the Cochrane risk-of-bias 2.0 tool. We ranked treatments according to their effectiveness in preventing AU flare using the P-score. RESULTS: We identified 752 citations and included 33 RCTs, comprising 4544 treated patients (anti-TNF mAb 2101, etanercept [ETN] 699, anti-IL17A 1744) and 2497 placebo-receiving patients. Incidence of uveitis was lower with anti-TNF mAb versus placebo (OR = 0.46; CI 95% [0.24; 0.90]) and versus anti-IL17A (OR = 0.34; CI 95% [0.12; 0.92]. According to the P-score, the ranking from the most to the least preventive treatment of uveitis flare was as follows: anti-TNF mAb, ETN, placebo, and anti-IL17A. CONCLUSION: In RCTs assessing anti-TNF and anti-IL17A in axSpA, incident uveitis are rare events. However, this network meta-analysis demonstrates that anti-TNF mAb are associated with a lower incidence of uveitis compared to placebo and anti-IL17A.
BACKGROUND:Anterior uveitis (AU) is the most frequent extra-articular feature of axial spondyloarthritis (axSpA). We aimed to assess and compare the incidence of AU in axSpA patients treated with anti-TNF or anti-IL17A. METHODS: We systematically reviewed PubMed, EMBase, and Cochrane from inception to May 3, 2020, and searched for placebo-controlled and head-to-head randomized controlled trials (RCTs) assessing anti-TNF monoclonal antibodies (mAb) or soluble receptor fusion protein or anti-IL17A in patients with axSpA according to ASAS criteria and reporting safety data on AU. Data were extracted following a predefined protocol. We did pairwise and network meta-analyses for the primary outcome of AU flares (relapse or de novo) incidence and estimated summary odds ratios (ORs). We assessed the quality of evidence using the Cochrane risk-of-bias 2.0 tool. We ranked treatments according to their effectiveness in preventing AU flare using the P-score. RESULTS: We identified 752 citations and included 33 RCTs, comprising 4544 treated patients (anti-TNF mAb 2101, etanercept [ETN] 699, anti-IL17A 1744) and 2497 placebo-receiving patients. Incidence of uveitis was lower with anti-TNF mAb versus placebo (OR = 0.46; CI 95% [0.24; 0.90]) and versus anti-IL17A (OR = 0.34; CI 95% [0.12; 0.92]. According to the P-score, the ranking from the most to the least preventive treatment of uveitis flare was as follows: anti-TNF mAb, ETN, placebo, and anti-IL17A. CONCLUSION: In RCTs assessing anti-TNF and anti-IL17A in axSpA, incident uveitis are rare events. However, this network meta-analysis demonstrates that anti-TNF mAb are associated with a lower incidence of uveitis compared to placebo and anti-IL17A.
Authors: Glenn J Jaffe; Andrew D Dick; Antoine P Brézin; Quan Dong Nguyen; Jennifer E Thorne; Philippe Kestelyn; Talin Barisani-Asenbauer; Pablo Franco; Arnd Heiligenhaus; David Scales; David S Chu; Anne Camez; Nisha V Kwatra; Alexandra P Song; Martina Kron; Samir Tari; Eric B Suhler Journal: N Engl J Med Date: 2016-09-08 Impact factor: 91.245
Authors: Elisabeth Lie; Ulf Lindström; Tatiana Zverkova-Sandström; Inge C Olsen; Helena Forsblad-d'Elia; Johan Askling; Meliha C Kapetanovic; Lars Erik Kristensen; Lennart T H Jacobsson Journal: Ann Rheum Dis Date: 2017-03-02 Impact factor: 19.103
Authors: J Christiaan van Denderen; Ingrid M Visman; Michael T Nurmohamed; Maria S A Suttorp-Schulten; Irene E van der Horst-Bruinsma Journal: J Rheumatol Date: 2014-08-01 Impact factor: 4.666
Authors: Quan Dong Nguyen; Pauline T Merrill; Glenn J Jaffe; Andrew D Dick; Shree Kumar Kurup; John Sheppard; Ariel Schlaen; Carlos Pavesio; Luca Cimino; Joachim Van Calster; Anne A Camez; Nisha V Kwatra; Alexandra P Song; Martina Kron; Samir Tari; Antoine P Brézin Journal: Lancet Date: 2016-08-16 Impact factor: 79.321
Authors: Janneke J de Winter; Leonieke J van Mens; Désirée van der Heijde; Robert Landewé; Dominique L Baeten Journal: Arthritis Res Ther Date: 2016-09-01 Impact factor: 5.156
Authors: Désirée van der Heijde; Atul Deodhar; Walter P Maksymowych; Joachim Sieper; Filip Van den Bosch; Tae-Hwan Kim; Mitsumasa Kishimoto; Andrew J Östör; Bernard Combe; Yunxia Sui; Yuanyuan Duan; Peter K Wung; In-Ho Song Journal: RMD Open Date: 2022-07